Results 151 to 160 of about 66,967 (213)

Functional analysis of BRCA1 and BRCA2 splicing variants using a minigene assay. [PDF]

Hum Genomics
Yim H, Youn S, Chae SW, Kim Y, Jang J, Cho SI, Lee JS, Seong MW.   +7 more
europepmc   +1 more source

Hyperthermia-induced BRCA2 reduction potentiates PARPi sensitivity in BRCA2-proficient ovarian carcinoma. [PDF]

Discov Oncol
Mei B, Li J, Hou X, Zhang J, Wang D, Huang J, Zhang G.   +6 more
europepmc   +1 more source

Molecular characteristics and prognostic insights into BRCA-associated breast cancer in Kazakhstan. [PDF]

Sci Rep
Samigatova A, Altaeva N, Suleimenov Y, Sibiryakov P, Zhabagin K, Zhakypbekkyzy Z, Seksenbayev B, Yoshihiro N, Tsigengagel O.   +8 more
europepmc   +1 more source

Sequential platinum and PARP Inhibition enhances PD1 immunotherapy efficacy in murine Brca2 mutated pancreatic cancer. [PDF]

Sci Rep
McVey JC, Wattenberg MM, Coho H, Infante K, Markowitz K, Delman D, Clendenin C, Furth EE, Tondon R, Stanger BZ, Vonderheide RH, Reiss KA, Beatty GL.   +12 more
europepmc   +1 more source

Prevalence of <i>BRCA1</i> and <i>BRCA2</i> Germline Mutations in Vietnamese Patients With Triple-Negative Breast Cancer. [PDF]

Cancer Control
Toan TT, To TV, Lan TTH, Thinh NV, Anh DTN, Hanh BTM.   +5 more
europepmc   +1 more source

BRCA1 positively regulates FOXO3 expression by restricting FOXO3 gene methylation and epigenetic silencing through targeting EZH2 in breast cancer [PDF]

, 2016
Gomes, AR, Gong, C, Lam, EW, Yao, S
core   +1 more source

A novel BRCA mutation classification system reveals differential responses to PARP inhibition and prognostic outcomes in epithelial ovarian cancer: a multicenter study. [PDF]

ESMO Open
Liu Q, Fan Y, Huang C, Wu M, Jin Y, Tao L, Liu Y, Song J, Wang S, Kong W, Huang X, Ha C, Cui Z, Zhao D, Yang X, Qiao J, Zhang Y, Li Y, Guo H.   +18 more
europepmc   +1 more source

A recurrent pathogenic BRCA2 truncating variant reveals a role for BRCA2-PCAF complex in modulating NF-κB-driven transcription. [PDF]

Nat Commun
Minello A, Gomez-Escudero J, Sridhara SC, Martin C, Girard E, Cañas JC, Memari Y, Bustos MR, Galarreta A, Boucherit V, Imyanitov E, Bodvarsdottir SK, Baulande S, Vincent-Salomon A, Servant N, Altmeyer M, Sigurdsson S, Stoppa-Lyonnet D, Nik-Zainal S, Carreira A.   +19 more
europepmc   +1 more source

Integrating breast tumour homologous recombination deficiency status to aid germline BRCA1 and BRCA2 variant classification. [PDF]

EBioMedicine
Fortuno C, Zhang J, Koufariotis LT, Hollway G, Wood S, Pearson JV, Simpson PT, Lakhani SR, McCart Reed AE, Thorne H, Mann GB, Skandarajah AR, Devereux L, Zhao Q, De Silva DL, Lindeman GJ, Waring P, James PA, Campbell I, Spurdle AB, Waddell N.   +20 more
europepmc   +1 more source

Cosegregation analysis following an excellent response to olaparib in a pancreatic cancer patient carrier of BRCA2:c.7892 T > C variant enables its reclassification from VUS to pathogenic. [PDF]

BJC Rep
Strojnik K, Blatnik A, Krajc M, Novaković A, Ignjatović M, Ocvirk J, Stegel V, Škerl P, Klančar G, Novaković S, Šetrajčič Dragoš V.   +10 more
europepmc   +1 more source